A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and TreatmentFrancesco Passamonti, Ayalew Tefferi, Jürgen Thiele et al.|Blood|2012Cited by 270
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Oleh Zagrijtschuk et al.|Blood|2015Cited by 186
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classificationJürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka et al.|Blood|2011Cited by 178
Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Jürgen Thiele et al.|American Journal of Hematology|2017Cited by 66
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, Bettina Gisslinger et al.|Leukemia|2015Cited by 62